TanoMed
Immunotherapy Solutions for GI Cancers
Health Tech & Life Sciences
Non Active, Feb 2022 ceased to operate
Company Overview
Snapshot
Founded in August 2020 by Helena Florindo and Ronit Satchi-Fainaro, TanoMed operated with 1–10 employees. The company ceased operations in February 2022.
Business overview
TanoMed specializes in developing precision immuno-oncology therapies for gastrointestinal cancers. The company's core technology involves dendritic cell-targeted nano-immunomodulator platforms designed to enhance therapeutic efficacy by priming T- and B-cells to trigger tumor destruction. TanoMed aims to expand the host antitumor specific T-effector phenotype and improve long-term tumor recognition, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Company Intelligence Q&A
- What is TanoMed's primary focus?
- TanoMed is focused on developing immunotherapy solutions specifically for gastrointestinal (GI) cancers.
- When was TanoMed founded?
- TanoMed was founded in August 2020.
- Who are the founders of TanoMed?
- TanoMed was founded by Helena Florindo and Ronit Satchi-Fainaro.
- What is TanoMed's core technology?
- TanoMed's core technology is a dendritic cell-targeted nano-immunomodulator platform that combines antigen-carrying capacity with in vivo targeting and modulation of DC function to enhance antitumor responses.
- What is the current status of TanoMed?
- TanoMed ceased to operate in February 2022.